Hercules Capital 過去の業績

過去基準チェック /46

Hercules Capitalは、平均年間15.6%の収益成長を遂げていますが、 Capital Markets業界の収益は、年間成長しています。収益は、平均年間2.6% 14.1%収益成長率で成長しています。 Hercules Capitalの自己資本利益率は17.4%であり、純利益率は64.4%です。

主要情報

15.6%

収益成長率

6.3%

EPS成長率

Capital Markets 業界の成長	15.2%
収益成長率	14.1%
株主資本利益率	17.4%
ネット・マージン	64.4%
前回の決算情報	30 Sep 2024

Recent updates

収支内訳

Hercules Capital の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

DB:19H 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費
30 Sep 24	494	318	75
30 Jun 24	486	278	76
31 Mar 24	477	331	76
31 Dec 23	461	334	73
30 Sep 23	438	277	76
30 Jun 23	406	302	73
31 Mar 23	362	197	70
31 Dec 22	322	100	66
30 Sep 22	294	42	63
30 Jun 22	280	12	62
31 Mar 22	277	105	60
31 Dec 21	281	172	60
30 Sep 21	284	319	59
30 Jun 21	284	339	58
31 Mar 21	282	318	59
31 Dec 20	287	226	59
30 Sep 20	283	120	58
30 Jun 20	281	96	59
31 Mar 20	283	83	62
31 Dec 19	268	173	61
30 Sep 19	254	111	61
30 Jun 19	238	128	58
31 Mar 19	218	132	53
31 Dec 18	208	76	51
30 Sep 18	201	111	50
30 Jun 18	194	109	50
31 Mar 18	193	90	49
31 Dec 17	191	78	47
30 Sep 17	188	74	48
30 Jun 17	187	72	47
31 Mar 17	182	48	46
31 Dec 16	175	67	46
30 Sep 16	167	67	43
30 Jun 16	169	41	47
31 Mar 16	164	34	47
31 Dec 15	157	41	47
30 Sep 15	155	48	48
30 Jun 15	145	59	43
31 Mar 15	140	69	38
31 Dec 14	144	70	36
30 Sep 14	140	74	31
30 Jun 14	144	96	32
31 Mar 14	145	104	33
31 Dec 13	140	98	32

質の高い収益: 19Hは高品質の収益を持っています。

利益率の向上: 19Hの現在の純利益率 (64.4%)は、昨年(63.2%)よりも高くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 19Hの収益は過去 5 年間で年間15.6%増加しました。

成長の加速: 19Hの過去 1 年間の収益成長率 ( 14.9% ) は、5 年間の平均 ( 年間15.6%を下回っています。

収益対業界: 19Hの過去 1 年間の収益成長率 ( 14.9% ) はCapital Markets業界10.8%を上回りました。

株主資本利益率

高いROE: 19Hの自己資本利益率 ( 17.4% ) は低いとみなされます。

Hercules Capital 過去の業績

過去 基準チェック /46

主要情報

最近の業績更新

Third quarter 2024 earnings released: EPS: US$0.43 (vs US$0.19 in 3Q 2023)

Hercules Capital, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Hercules Capital, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: EPS: US$0.26 (vs US$0.66 in 2Q 2023)

Hercules Capital, Inc. to Report Q2, 2024 Results on Aug 01, 2024

First quarter 2024 earnings released: EPS: US$0.58 (vs US$0.69 in 1Q 2023)

Recent updates

Third quarter 2024 earnings released: EPS: US$0.43 (vs US$0.19 in 3Q 2023)

Second quarter dividend of US$0.48 announced

Hercules Capital, Inc. Declares Cash Distribution for the Third Quarter 2024, Payable on November 20, 2024

Hercules Capital, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Hercules Capital, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Hologic, Inc. (NasdaqGS:HOLX) agreed to acquire Gynesonics, Inc. for $350 million.

KARL STORZ Endoscopy-America, Inc. completed the acquisition of Asensus Surgical, Inc. (NYSEAM:ASXC).

KARL STORZ Endoscopy-America, Inc. completed the acquisition of Asensus Surgical, Inc. (NYSEAM:ASXC).

Second quarter 2024 earnings released: EPS: US$0.26 (vs US$0.66 in 2Q 2023)

First quarter dividend of US$0.48 announced

Hercules Capital, Inc. Declares Cash Distribution for the Second Quarter 2024, Payable on August 20, 2024

Hercules Capital, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Haveli Investments Software Fund I, L.P., a fund managed by Haveli Investment Management LLC completed the acquisition of ZeroFox Holdings, Inc. (NasdaqGM : ZFOX) from Monarch Alternative Capital LP and Others.

First quarter dividend of US$0.48 announced

First quarter 2024 earnings released: EPS: US$0.58 (vs US$0.69 in 1Q 2023)

Hercules Capital, Inc. Declares First Quarter Cash Dividend, Payable on May 14, 2024

Hercules Capital, Inc., Annual General Meeting, Jun 20, 2024

Hercules Capital, Inc. to Report Q1, 2024 Results on May 02, 2024

KARL STORZ SE & Co. KG entered into an agreement to acquire Asensus Surgical, Inc. (NYSEAM:ASXC) for $100 million.

Upcoming dividend of US$0.48 per share

Full year 2023 earnings released: EPS: US$2.34 (vs US$0.80 in FY 2022)

Hercules Capital, Inc. Declares Cash Distribution for the Fourth Quarter 2023, Dividend Payable on March 6, 2024

Haveli Investments Software Fund I, L.P., a fund managed by Haveli Investment Management LLC entered into an Agreement and Plan of Merger to acquire ZeroFox Holdings, Inc. (NasdaqGM : ZFOX) from Monarch Alternative Capital LP and Others for approximately $150 million.

Hercules Capital, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Upcoming dividend of US$0.48 per share at 12% yield

Third quarter 2023 earnings released: EPS: US$0.19 (vs US$0.41 in 3Q 2022)

Hercules Capital, Inc. Declares Total Cash Distribution the Third Quarter 2023, Payable on November 22, 2023

Hercules Capital, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New major risk - Revenue and earnings growth

Hercules Capital Appoints Nikos Theodosopoulos an Independent Member of its Board of Directors and to Serve on Audit Committee

Upcoming dividend of US$0.48 per share at 11% yield

Hercules Capital, Inc. has completed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: EPS: US$0.67 (vs US$0.088 loss in 2Q 2022)

Hercules Capital Declares Cash Distribution for the Second Quarter 2023, Payable August 25, 2023

Hercules Capital, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Hercules Capital, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Independent Director recently bought €89k worth of stock

Independent Director recently bought €89k worth of stock

First quarter 2023 earnings released: EPS: US$0.70 (vs US$0.033 loss in 1Q 2022)

Investor sentiment deteriorates as stock falls 20%

Upcoming dividend of US$0.47 per share at 13% yield

Full year 2022 earnings released: EPS: US$0.80 (vs US$1.50 in FY 2021)

Hercules Capital Increases Its Quarterly Cash Distribution for the Fourth Quarter of 2022, Payable on March 9, 2023

Hercules Capital, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Hercules Capital, Inc. Announces Resignation of Brad Koenig as Member of the Board

Third quarter 2022 earnings released: EPS: US$0.42 (vs US$0.20 in 3Q 2021)

Upcoming dividend of US$0.51 per share

Sumitovant Biopharma Ltd. signed an agreement to acquire a 47.83% stake in Myovant Sciences Ltd for $1.2 billion.

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of ChemoCentryx, Inc. (NasdaqGS:CCXI) from a group of shareholders.

Hercules Capital, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Hercules Capital, Inc. Declares Cash Distribution for the Third Quarter of 2022, Payable on November 17, 2022

Sumitovant Biopharma Ltd. entered into a non-binding proposal to acquire Myovant Sciences Ltd. (NYSE:MYOV) for $1.2 billion.

Upcoming dividend of US$0.50 per share

Second quarter 2022 earnings released: US$0.083 loss per share (vs US$0.71 profit in 2Q 2021)

Hercules Capital, Inc. Increases Quarterly Cash Distribution for the Second Quarter of 2022, Payable on August 16, 2022

Hercules Capital, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Hercules Capital, Inc. Appoints Deanne Aguirre to its Board of Directors

First quarter 2022 earnings released: US$0.028 loss per share (vs US$0.56 profit in 1Q 2021)

Hercules Capital, Inc. Announces Cash Distribution for the First Quarter of 2022, Payable on May 24, 2022

Hercules Capital, Inc., Annual General Meeting, Jun 23, 2022

Hercules Capital, Inc. to Report Q1, 2022 Results on May 05, 2022

Upcoming dividend of US$0.48 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Hercules Capital Declares Cash Distribution for the Fourth Quarter of 2021, Payable on March 16, 2022

Hercules Capital, Inc. to Report Q4, 2021 Results on Feb 22, 2022

Hercules Capital, Inc. Announces Executive Changes

High number of new directors

High number of new directors

過去基準チェック /46